TNXP
Tonix Pharmaceuticals Holding Corp.
0.16
-
0.01
3.52%
24 x 0.16
24 x 0.16
bid
ask
24 @ 04:00 PM
0.16+0.00 (0.13%)
![](/assets/images/down.png)
![](/assets/images/up.png)
sentiment
0.15
day range
0.17
0.15
52 week range
30.08
Prev Close0.16
Open0.17
Low0.15
High0.17
Volume9.08M
Avg. Volume15.53M
Market Cap3.62M
Inst. Own1.82%
Beta2.10
Short Ratio0.55
Div & Yield0.00 /
EPS-134.18
P/E0.00
1yr Target22.33
50day MA0.54
200day MA7.07
^DJI
Dow Jones Industrial Average
40755.80
04:45 PM
-
219.20
0.53%
^IXIC
NASDAQ Composite
17127.70
05:15 PM
+
43.40
0.25%
^GSPC
S&P 500
5503.41
04:45 PM
-
16.66
0.30%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-16 | 2024-06 | -9.91 | -19.28 | -9.37 | -94.55% |
2024-05-13 | 2024-03 | -16.61 | -5.75 | 10.86 | 65.38% |
2024-04-01 | 2023-12 | -49.84 | -27.48 | 22.36 | 44.86% |
2023-11-09 | 2023-09 | -47.6 | -58.47 | -10.87 | -22.84% |
2023-08-10 | 2023-06 | -88.82 | -85.62 | 3.2 | 3.60% |
2023-05-08 | 2023-03 | -79.87 | -103.83 | -23.96 | -30.00% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-31 | Alliance Global Partners | Upgrade | Buy | Buy |
2023-06-01 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-30 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-10 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-02-24 | Alliance Global Partners | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-08-12 | BAGGER RICHARD H | Director | 10.00K | Purchase |
2020-08-19 | BELL MARGARET SMITH | Director | 5.39K | Purchase |
2021-05-24 | GOODMAN DANIEL WINTNER M.D. | Director | 5.00K | Purchase |
2022-06-28 | LEDERMAN SETH | Chief Executive Officer | 0.00 | Purchase |
2018-06-24 | MARIO ERNEST B | Director | 0.00 | Purchase |
2018-06-13 | MORRIS JESSICA EDGAR | Chief Operating Officer | 1.64K | Purchase |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 398.75K | 630.03K | 2.24% |
2023-06-29 | Renaissance Technologies, LLC | 211.42K | 334.05K | 1.19% |
2023-06-29 | Geode Capital Management, LLC | 85.37K | 134.88K | 0.48% |
2023-06-29 | Acadian Asset Management. LLC | 68.74K | 108.61K | 0.39% |
2023-06-29 | Blackrock Inc. | 48.34K | 76.38K | 0.27% |
2023-06-29 | Raymond James & Associates, Inc. | 44.36K | 70.10K | 0.25% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 297.30K | 469.74K | 1.67% |
2023-06-29 | Vanguard Extended Market Index Fund | 100.84K | 159.33K | 0.57% |
2023-05-30 | Fidelity Extended Market Index Fund | 49.98K | 89.47K | 0.28% |
2023-05-30 | Fidelity Total Market Index Fund | 13.51K | 24.18K | 0.08% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.14K | 16.35K | 0.05% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 6.31K | 6.10K | 0.04% |
Split
...
Split | Date |
---|---|
1 : 32 | 2024-06-10 |
4 : 25 | 2023-05-10 |
1 : 32 | 2022-05-17 |
1 : 10 | 2019-11-01 |
1 : 10 | 2018-11-28 |
1 : 10 | 2017-03-17 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Tonix Pharm stock hits 52-week low at $0.15 amid steep decline
news.google.com • -
Tonix Pharm stock hits 52-week low at $0.15 amid steep decline
news.google.com • -
Tonix Pharmaceuticals expands offering to $150 million
news.google.com • -
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
globenewswire.com • -
Tonix Pharmaceuticals Announces Proposed Public Offering
globenewswire.com • -
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
globenewswire.com • -
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
investorplace.com • -
Tonix Pharmaceuticals Announces Proposed Public Offering
globenewswire.com •